share_log

翰森製藥:截至二零二四年六月三十日止六個月中期業績公告

HANSOH PHARMA: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024

HKEX ·  Aug 27 10:17

Summary by Moomoo AI

翰森制药集团有限公司(「本公司」)公布截至2024年6月30日止六个月的未经审核中期业绩。期内,公司及其附属公司(统称「本集团」)实现收入约人民币65.06亿元,同比增长约44.2%;创新药与合作产品收入约人民币50.32亿元,同比增长约80.6%,占收入比例约77.4%;研发开支约人民币11.96亿元,同比增长约28.7%,占收入比例约18.4%;溢利约人民币27.26亿元,同比增长约111.5%;每股基本盈利约人民币0.46元,同比增长约111.4%。期内收入、溢利及每股基本盈利增加主要由于创新药与合作产品收入增加所致。本公司持续创新,致力于成为全球领先的创新驱动型制药企业。截至报告期末,...展開全部
翰森制药集团有限公司(「本公司」)公布截至2024年6月30日止六个月的未经审核中期业绩。期内,公司及其附属公司(统称「本集团」)实现收入约人民币65.06亿元,同比增长约44.2%;创新药与合作产品收入约人民币50.32亿元,同比增长约80.6%,占收入比例约77.4%;研发开支约人民币11.96亿元,同比增长约28.7%,占收入比例约18.4%;溢利约人民币27.26亿元,同比增长约111.5%;每股基本盈利约人民币0.46元,同比增长约111.4%。期内收入、溢利及每股基本盈利增加主要由于创新药与合作产品收入增加所致。本公司持续创新,致力于成为全球领先的创新驱动型制药企业。截至报告期末,本集团共获批上市七款创新药,均已被纳入中国国家医疗保障局(「NHSA」)发布的《国家基本医疗保险、工伤保险和生育保险药品目录》(「国家医保目录」)。本公司不断提升完善环境、社会及管治水平,于本年内继续入选标普全球(S&P Global)发布的《可持续发展年鉴(中国版)2024》,蝉联ESG评分位列行业最佳1%。
Hansen Pharmaceutical Group Limited (the 'Company') announced its unaudited interim results for the six months ended June 30, 2024. During the period, the Company and its subsidiaries (collectively the 'Group') achieved a revenue of approximately RMB 6.506 billion, an increase of approximately 44.2% year-on-year; revenue from innovative drugs and collaborative products was approximately RMB 5.032 billion, an increase of approximately 80.6%, accounting for approximately 77.4% of the revenue; research and development expenses were approximately RMB 1.196 billion, an increase of approximately 28.7%, accounting for approximately 18.4% of the revenue; net profit was approximately RMB 2.726 billion, an increase of approximately 111.5%; basic earnings per share was approximately RMB 0.46, an increase of approximately 111.4%. The increase in revenue, net profit, and basic earnings per share during the period was mainly due to...Show More
Hansen Pharmaceutical Group Limited (the 'Company') announced its unaudited interim results for the six months ended June 30, 2024. During the period, the Company and its subsidiaries (collectively the 'Group') achieved a revenue of approximately RMB 6.506 billion, an increase of approximately 44.2% year-on-year; revenue from innovative drugs and collaborative products was approximately RMB 5.032 billion, an increase of approximately 80.6%, accounting for approximately 77.4% of the revenue; research and development expenses were approximately RMB 1.196 billion, an increase of approximately 28.7%, accounting for approximately 18.4% of the revenue; net profit was approximately RMB 2.726 billion, an increase of approximately 111.5%; basic earnings per share was approximately RMB 0.46, an increase of approximately 111.4%. The increase in revenue, net profit, and basic earnings per share during the period was mainly due to the increase in revenue from innovative drugs and collaborative products. The Company continues to innovate and is committed to becoming a global leading innovation-driven pharmaceutical company. As of the end of the reporting period, the Group has obtained market approval for seven innovative drugs, all of which have been included in the National Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List released by the National Healthcare Security Administration (NHSA). The Company continuously improves its environmental, social, and governance performance and has been selected once again in the S&P Global Sustainability Yearbook (China Edition) 2024, ranking among the top 1% in the industry for ESG scores.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

    Statement

    This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.